ApeX Therapeutics

ApeX Therapeutics is a clinical-stage biotechnology company dedicated to the development of small molecule inhibitors targeting the APE1/Ref-1 protein. The company's primary focus is on its lead asset, APX3330, which utilizes a unique mechanism of action to address both inflammatory and angiogenic pathways in retinal diseases and oncology. Originally a spin-out from Indiana University, ApeX successfully advanced APX3330 through early clinical trials before licensing the global rights for ophthalmic indications to Ocuphire Pharma in 2020. The company's research highlights the role of redox signaling in disease progression, offering a novel approach to treating conditions like diabetic retinopathy and age-related macular degeneration.